Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Jan 19, 2021 8:03am EST

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

Jan 11, 2021 8:00am EST

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

Jan 07, 2021 8:00am EST

Algernon Pharmaceuticals Announces Plans for 2021

Dec 30, 2020 8:00am EST

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Dec 24, 2020 11:42am EST

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Dec 23, 2020 7:40pm EST

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

Dec 21, 2020 8:00am EST

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

Dec 17, 2020 8:00am EST

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

Dec 16, 2020 7:43pm EST

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Dec 15, 2020 8:15am EST

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • …
  • …Page 22
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap